Medtronic PLC (MDT, Financial) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019. Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments. Medtronic PLC has a market cap of $133.08 billion; its shares were traded at around $99.26 with a P/E ratio of 29.02 and P/S ratio of 4.41. The dividend yield of Medtronic PLC stocks is 2.01%. Medtronic PLC had annual average EBITDA growth of 6.30% over the past ten years. GuruFocus rated Medtronic PLC the business predictability rank of 5-star.
For the last quarter Medtronic PLC reported a revenue of $8.1 billion, compared with the revenue of $8.1 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $30.6 billion, an increase of 2% from last year. For the last five years Medtronic PLC had an average revenue growth rate of 12.5% a year.
The reported diluted earnings per share was $3.41 for the year, an increase of 50.2% from previous year. Over the last five years Medtronic PLC had an EPS growth rate of 1.7% a year. The Medtronic PLC enjoyed an operating margin of 21.7%, compared with the operating margin of 21.18% a year before. The 10-year historical median operating margin of Medtronic PLC is 25.10%. The profitability rank of the company is 9 (out of 10).
At the end of the fiscal year, Medtronic PLC has the cash and cash equivalents of $4.4 billion, compared with $3.7 billion in the previous year. The long term debt was $24.5 billion, compared with $23.7 billion in the previous year. The interest coverage to the debt is 4.6. Medtronic PLC has a financial strength rank of 6 (out of 10).
At the current stock price of $99.26, Medtronic PLC is traded at 24.9% premium to its historical median P/S valuation band of $79.47. The P/S ratio of the stock is 4.41, while the historical median P/S ratio is 3.53. The intrinsic value of the stock is $36.60 a share, according to GuruFocus DCF Calculator. The stock gained 17.57% during the past 12 months.
Directors and Officers Recent Trades:
- Director Richard H Anderson bought 10,900 shares of MDT stock on 05/24/2019 at the average price of $92.4. The price of the stock has increased by 7.42% since.
- SVP, Chief HR Officer Carol A Surface sold 9,000 shares of MDT stock on 06/17/2019 at the average price of $97.66. The price of the stock has increased by 1.64% since.
- EVP & Group President Diabetes Hooman Hakami sold 52,664 shares of MDT stock on 06/12/2019 at the average price of $97.49. The price of the stock has increased by 1.82% since.
- EVP & GroupPres Restora Therap Geoffrey Martha sold 11,000 shares of MDT stock on 06/06/2019 at the average price of $96.05. The price of the stock has increased by 3.34% since.
- EVP & President EMEA Hoedt Rob Ten sold 9,000 shares of MDT stock on 05/28/2019 at the average price of $91.88. The price of the stock has increased by 8.03% since.
For the complete 20-year historical financial data of MDT, click here.
